Welcome to our dedicated page for Inozyme Pharma SEC filings (Ticker: INZY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing loaded with pharmacokinetic charts, trial protocols, and revenue-less cash-flow tables can feel overwhelming. Inozyme Pharma’s SEC disclosures are especially dense because every 10-Q must outline patient-enrollment updates, orphan-drug milestones, and runway projections. Investors who just want to know whether INZ-701 hit a safety endpoint—or if directors are accumulating stock—shouldn’t wade through 200 pages.
Stock Titan turns those complexities into clarity. Our AI-powered summaries flag exactly where “understanding Inozyme Pharma SEC documents with AI” matters: the section explaining ENPP1 and ABCC6 data in the Inozyme Pharma quarterly earnings report 10-Q filing, risk-factor shifts in the Inozyme Pharma annual report 10-K simplified, and any surprise Inozyme Pharma 8-K material events explained. Real-time alerts on Inozyme Pharma insider trading Form 4 transactions and Inozyme Pharma executive stock transactions Form 4 arrive seconds after EDGAR posts, letting you gauge leadership sentiment before the market reacts.
Every filing type is covered—from the Inozyme Pharma proxy statement executive compensation that details option grants to the S-3 shelf registration outlining future capital needs. Use our platform to:
- Compare R&D spend across periods with the Inozyme Pharma earnings report filing analysis.
- Track each Inozyme Pharma Form 4 insider transactions real-time notice for buying or selling patterns.
- Download study-level data tables straight from exhibits without searching.
Whether you ask, “What does Inozyme Pharma report in their SEC filings?” or “Where can I find an Inozyme Pharma quarterly earnings report 10-Q filing?”, you’ll land here. Explore “Inozyme Pharma SEC filings explained simply” and move from raw data to actionable insight in minutes—AI explained, investor approved.
Inozyme Pharma COO Matthew Winton acquired 14,355 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP). The shares were purchased at $0.74 per share, representing 85% of the closing price on April 1, 2025, the first day of the purchase period.
Following this transaction, Winton's direct beneficial ownership increased to 21,743 shares. The purchase was made during the ESPP period running from April 1, 2025, through June 25, 2025.
- Transaction Type: Stock Purchase through ESPP
- Purchase Price: $0.74 per share (15% discount)
- Ownership Form: Direct
- Filing Status: Individual filing
This insider purchase through the ESPP demonstrates continued participation in company equity programs by key executive leadership.
Insider Trading Alert: Douglas A. Treco, CEO & Chairman of Inozyme Pharma (NASDAQ: INZY), acquired 2,815 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key Transaction Details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- Total shares owned after transaction: 43,861 shares
- Ownership type: Direct
- ESPP purchase period: April 1, 2025 - June 25, 2025
The transaction was executed under the company's 2020 ESPP, which allows employees to purchase company stock at a discount. This insider purchase by the CEO demonstrates continued alignment with shareholder interests and potential confidence in the company's prospects.
Inozyme Pharma (INZY) SVP, CFO & Head of BD Sanjay Subramanian reported the acquisition of 6,813 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key transaction details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- ESPP purchase period: April 1, 2025 - June 25, 2025
- Total shares owned after transaction: 39,701 shares
- Ownership form: Direct
This insider purchase through the ESPP demonstrates continued participation in company equity programs by a key executive officer. The transaction was executed under the company's 2020 Employee Stock Purchase Plan, which allows employees to purchase shares at a discount to market price.
Inozyme Pharma has announced the postponement of its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, 2025, due to a pending acquisition by BioMarin Pharmaceutical. If the acquisition completes, no public stockholder annual meeting will be held. If it doesn't proceed, the Board will reschedule the meeting with a new record date.
Key Company Profile:
- Clinical-stage biopharmaceutical company with ~50 Boston-based employees
- Focuses on PPi-Adenosine Pathway therapeutics for bone health and blood vessel function
- Lead therapy INZ-701, an ENPP1 Fc fusion protein, is in late-stage clinical trials
- Target conditions include ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis
The filing includes detailed information about the tender offer process and directs stockholders to review important acquisition-related documents filed with the SEC by both companies. Materials are available on the SEC website and both companies' respective websites.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
What is the core focus of Inozyme Pharma, Inc.?
Which conditions are primarily targeted by the company?
What is INZ-701?
How does INZ-701 work in the body?
What stage of development is Inozyme Pharma currently in?
Why is the PPi-Adenosine pathway significant?
How does Inozyme Pharma differentiate itself from its competitors?
What is the potential impact of Inozyme Pharma's research?
Are there any approved therapies for the targeted diseases?
